Purpose: "Lock-in" programs (LIPs) are used by health insurers to address potential substance (eg, opioid) misuse among beneficiaries. We sought to (1) examine heterogeneity in trajectories of dispensed opioids (in average daily morphine milligram equivalents (MMEs)) over time: prior to, during, and following release from a LIP, and (2) assess associations between trajectory patterns and beneficiary characteristics.
potential overutilization of prescription drugs and controlling their access. 4, 5 LIPs typically require beneficiaries to use a single prescriber and/or pharmacy to obtain opioids and other specific prescription drugs (eg, benzodiazepines) for a specified period of time, such as 1 year.
We previously reported that North Carolina's (NC) Medicaid LIP was associated with reductions in numbers of controlled substance prescriptions, including opioids, dispensed per person per month both while enrolled in the LIP and following release from the program, as compared to a period prior to lock-in. 6 However, average dosages of opioids dispensed (in average daily morphine milligram equivalents (MMEs)) to beneficiaries were elevated during LIP enrollment and in the period soon after release from the program.
While understanding the average impact of the program across the LIP-enrolled population is important, this approach can also mask heterogeneous patterns of LIP response. Indeed, prior research
indicates that trajectories of substance use vary markedly across populations. [7] [8] [9] [10] [11] [12] Analyzing variation in opioid dispensing patterns across the LIP-enrolled population can help us better understand who responds to LIPs and in turn help more effectively target limited program resources. In this study, we (1) described heterogeneity in trajectories of dispensed average daily MMEs in a LIP-enrolled beneficiary population and (2) examined beneficiary characteristics associated with trajectory patterns.
| METHODS

We analyzed Medicaid claims linked to Prescription Drug Monitoring
Program records for a cohort of beneficiaries enrolled in the NC Medicaid LIP between October 2010 and September 2012 (n = 2701).
Using latent class growth analyses (LCGA) 13 , we estimated trajectories of average daily MMEs of opioids dispensed across months prior to, during, and after release from the LIP. We then examined associations between trajectory patterns and beneficiary characteristics.
| Data sources
As previously described, 6, 14 This study was approved by the University of North Carolina at Chapel Hill's Institutional Review Board.
| NC Medicaid LIP
The NC Medicaid LIP originated in October 2010. 15 Medicaid beneficiaries were eligible for the LIP if they met any of the following criteria within 2 consecutive calendar months: (1) filling more than 6 opioid prescriptions, (2) filling more than 6 benzodiazepine prescriptions, or (3) filling opioid or benzodiazepine prescriptions that were written by more than 3 different prescribers. 15 Each month, a vendor, working with the state, determined who was eligible for the LIP by examining Medicaid prescription dispensing information for the previous 2 months. The vendor then prioritized eligible beneficiaries using a proprietary algorithm combined with a review by pharmacists. Beneficiaries in hospice care, with cancer, in a skilled nursing facility, dually eligible for Medicaid and Medicare, or <18 years were generally not considered for LIP enrollment.
Based on the prioritization process, approximately 200 of the highest ranking beneficiaries were recommended to the state for LIP enrollment each month. Once approved, the approximately 200 beneficiaries were notified of their selection for mandatory program enrollment and were informed that LIP enrollment restricted them, for a 1-year period, to using 1 prescriber and 1 pharmacy location to obtain opioid and benzodiazepine prescriptions. Beneficiaries were given 30 days to select a preferred prescriber and pharmacy before restrictions began; those who did not were assigned 1 of each.
| Study cohort
We established and followed a historical cohort of adults between the ages of 18 and 64 years who were initially enrolled in the LIP between October 2010 and September 2012. Beneficiaries in our cohort were followed from the first day that they received an opioid prescription on or after October 1, 2009 (the first date for which we had data), throughout their period of lock-in, and up to 1 year post-program
KEY POINTS
• "Lock-in" programs are used by health plans across the country with the goal of identifying beneficiaries demonstrating potential overutilization of prescription drugs (eg, opioids) and controlling their access.
• Analyzing variation in opioid dispensing patterns across a "lock-in"-enrolled population can help us better understand underlying heterogeneity in program impacts and in turn help more effectively target program resources.
• Five patterns provided a suitable summary of the heterogeneity in opioid dispensing trajectories.
• Overall, the program appeared to have a limited impact on trajectory patterns.
• However, strong associations between trajectory patterns and beneficiaries' demographics, substance use-related characteristics, comorbid conditions, and healthcare utilization provide insight into potential program design modifications that might improve impact.
release or until June 30, 2013 (the last date for which we had data).
Because we were particularly interested in understanding different trajectory paths during and after lock-in, we required cohort beneficiaries to have either remained continuously enrolled in the LIP (and therefore also Medicaid) for their assigned 1-year LIP period or to have remained continuously enrolled in the LIP through June 2013, the last month for which we had data (ie, administrative censoring). We defined continuous enrollment as no more than a 7-day gap in Medicaid coverage. Less than 1% of beneficiaries enrolled in the LIP were enrolled for longer than a year; they were not included in this study.
| Measures
| Outcome measure
We examined trajectories of average daily MMEs of dispensed opioids.
Average daily MME is a research measure used to compare diverse opioid medication regimens using morphine equivalents as a standardized unit. 16 To calculate the average daily MME of a given opioid prescription, we multiplied the drug's strength by the quantity received and a medication-specific MME conversion factor and divided by the days' supply received. 17 The average daily MME for each prescription was then applied to all days for which the prescription was to be taken, according to the days' supply. If a beneficiary had more than 1 opioid prescription active on a given day, the MMEs for all prescriptions to be taken on that day were summed. We included MMEs from all sources of payment. Prescriptions for medication-assisted treatment (MAT) for opioid use disorders were not included. For modeling purposes, we averaged each beneficiary's average daily MMEs across each calendar month. This monthly average measure was then log transformed to obtain an approximately normal distribution for improved model estimation. 
| Covariate measures
Covariates included demographics, substance use-related characteristics, comorbid conditions, and overall healthcare utilization. 
| Overview of statistical models
We used an application of finite mixture modeling, LCGA, to estimate trajectories of average daily MMEs of opioids dispensed to beneficiaries across specific time periods of interest (prior to lock-in, during lock-in, and following release from lock-in). LCGA models identify clusters of individuals that follow approximately the same trajectory for an outcome of interest and can be used as a tool for approximating a complex, unknown distribution of trajectories across the larger population. 13, 18, 19 As a preliminary step, it was necessary to determine how to model the functional form of change in average daily MMEs dispensed over time. We considered and evaluated several model functional forms, using an unconditional LCGA model. We determined that a 5-piece, linear piecewise specification (ie, a model with 5 linear pieces joined by 4 knots) provided the best fit. Knots (ie, points at which slopes were permitted to change) were placed at natural and observed change points, including at the first month of lock-in and at the first month of program release. Additionally, extensive previous analyses revealed a specific spike period with a sharp rise in dispensed opioid prescriptions (and corresponding MMEs), beginning approximately 6 months prior to lock-in. 6 The spike generally peaked 3 months prior to enrollment with a decline thereafter; therefore, knots were also placed at 3 and 6 months prior to lock-in. The spike period appeared to represent the trigger for LIP enrollment for many of these beneficiaries. The large spike is likely because the cohort included those who were selected into the LIP (and therefore were the highest users of prescribed opioids at a specific point in time). The deescalation period is then regarded as a subsequent regression to the mean.
We then conducted a series of analyses to determine how many discrete classes were needed to adequately summarize heterogeneity in growth trajectories. We evaluated 1 through 8 class solutions. Full details on the model selection process and criteria used to determine the number of meaningful trajectory classes can be found in the online appendix. All models were fit in Mplus, version 7.4.
| Covariate associations with trajectory classes
LCGA models produce probabilities of belonging to each trajectory class for each beneficiary. Using these posterior probabilities, we estimated the prevalence of beneficiary characteristics within each trajectory class. For each class, we calculated weighted (ie, weights were posterior probabilities) counts and percentages for categorical covariates and means (with corresponding 25th, 50th, and 75th percentiles) for continuous covariates.
To provide a clearer depiction of covariate relationships with latent classes, we also calculated and graphed standardized differences using the largest class as the reference class. Standardized differences provide a measure of the similarity or dissimilarity of 2 groups with respect to specific covariates. Additional details on these calculations can be found in the online appendix. All analyses of covariate associations with trajectory class were completed in SAS 9.4.
| RESULTS
Between October 2010 and September 2012, 2701 beneficiaries were enrolled in the LIP and remained enrolled in the LIP for a full 1-year period (or remained continuously enrolled prior to being administratively censored in June 2013). Beneficiaries were largely female (70%), white (74%), and had a mean age of 39 years (Table 1) . Nearly one-third (32.2%) had a substance use disorder diagnosis in the year prior to LIP enrollment, and beneficiaries had on average 10 emergency department visits in the prior year, although the distribution was skewed (mean = 9.9; median = 6). Beneficiaries also exhibited a high prevalence of pain and mental health-related diagnoses (eg, 83%
back pain diagnosis; 62% depression diagnosis) in the year prior to program enrollment.
| Trajectories
We used several model fit criteria to determine the ideal number of latent classes to describe heterogeneity in trajectories of MMEs of dispensed opioids (see online appendix for details). The 5-class solution was ultimately selected as the best solution. The final model had high entropy (0.97) with most beneficiaries having a very high probability of belonging to 1 specific class and low probabilities of belonging to others (Table A3 , online appendix).
All 5 trajectories demonstrated a large spike in average daily MMEs of opioids dispensed during the 6 months prior to LIP enrollment ( Figure 1 ). As described above, this escalation period is assumed to be the primary trigger for LIP enrollment. We characterize the 5 trajectory classes (C) according to their MME levels prior to the spike and following LIP release as follows:
C1. Start high (approx. >90 avg. daily MMEs), end high (13.1% of the cohort).
C2. Start medium (approx. 20-89 avg. daily MMEs), end medium (13.2%).
C3. Start medium, end low (approx. <20 avg. daily MMEs) (21.5%).
C4. Start low, end medium (22.6%).
C5. Start low, end low (29.6%).
More than half (56%) of the LIP-enrolled cohort appeared to cluster around trajectory patterns characterized by a relatively stable level of daily MMEs prior to, during, and following the LIP (ie, C1, C2, and C5). Prior to becoming eligible (ie, pre-spike), these 3 trajectory groups were at high, medium, and low levels of MMEs respectively, and all 3 were at essentially the same levels following LIP release.
On the other hand, trajectories C3 and C4 were characterized by considerable change across periods. Compared to their prespike period, C4 (23%) had an unexpected increase in MME dosage during lock-in and following release. Of the 5 groups, only C3 (22%) exhibited a decline in dispensed MMEs during the lock-in period. However, this decline was evident prior to the point of actual LIP enrollment, and therefore, a causal association remains questionable.
| Covariate associations with trajectories
Covariate similarities and differences were summarized (Tables 1   and 2 ; Figure 2 ). Comparisons of particular interest are presented below.
| C1 and C2 (sustained high or medium MMEs) compared to C5 (sustained low MMEs)
Approximately one-quarter of our cohort tended to obtain average daily MMEs in high or medium dosage amounts across all time periods (ie, C1
and C2). Despite their different MME levels, beneficiaries that clustered around these 2 trajectories tended to be similar in their covariate profiles. They were older, on average, than other trajectory classes and tended to have higher levels of chronic pain, disability, and comorbidity. At the other extreme, beneficiaries following C5, a trajectory characterized by sustained low levels of MME dispensing,
were the youngest of all classes, had the lowest levels of chronic pain, comorbidity, and disability, and had the highest levels of treatment for opioid use disorder. c Assessed using a 1-year lookback period from the date of "lock-in" program enrollment.
| C2 and C3 (both began at medium MMEs, C3 declined while C2 remained level)
C2 and C3 were relatively similar in pre-spike levels of dispensed MMEs but differed considerably with respect to post-spike trajectories. C3
exhibited a large decline in MMEs following the spike in opioid dispensing, in contrast to C2's sustained levels. While beneficiaries who tended to follow these patterns were generally similar in average covariate characteristics, beneficiaries clustered around a C3 trajectory had the highest prevalence of overdose events and substance-related disorder diagnoses prior to LIP enrollment, as well as a relatively high prevalence of MAT and mental health disorder diagnoses.
| C4 and C5 (both began at low MMEs, C4 elevated while C5 remained low)
C4 and C5 were similar in pre-spike levels of dispensed MMEs. However, C5 returned to a low level of MME dispensing following the spike, while C4 remained at a heightened level following the spike. Most striking was the difference in MAT use associated with these 2 trajectories: Similar to C1 in many characteristics (eg, age, gender, Medicaid eligibility category, pain diagnoses); different than C1 in greater use of ED; slightly lower prevalence of other substance-related disorder diagnoses C3: Start medium, end low Younger than C1 and C2; less disability than C1 and C2; greater use of MAT than C1 and C2; highest prevalence of other substance use-related disorders and overdose; greater use of ED than C1 and C2 and similar to C4 and C5; higher prevalence of mental health disorders than C1 and C2 and similar to C4 and C5 C4: Start low, end medium Similar in age to C3, older than C5; larger proportion of women than C1-C3, similar to C5; lower prevalence of disability than C1-C3, more than C5; similar use of MAT to C3 but lower than C5; similar prevalence of pain diagnoses to C3, higher than C5; similar prevalence of mental health diagnoses to C3 and C5; higher mean comorbidity index than C5, similar to C3 C5: Start low, end low Younger than C1-C4; highest prevalence of women; lowest prevalence of disability; very high prevalence of MAT (highest of any class); highest use of EDs; lowest prevalence of severe pain diagnoses; high prevalence of mental health disorders, similar to C3 and C4 and higher than C1 and C2; lowest comorbidity index C, class (trajectory); MAT, medication-assisted treatment; ED, emergency department.
C5 had the highest use of MAT, nearly 4 times that of C4. Other notable differences included a higher prevalence of beneficiaries receiving Medicaid benefits because of a disability, a higher prevalence of severe pain diagnoses, and a higher mean comorbidity index among beneficiaries following a C4 trajectory.
| DISCUSSION
Among a beneficiary population receiving large numbers of opioid prescriptions and continuously enrolled in a Medicaid LIP, considerable heterogeneity existed in the trajectories of opioid dosages (MMEs) dispensed prior to, during, and following release from the program.
We found that 5 trajectory patterns provided a suitable summary of the underlying heterogeneity in MME trajectories and that there were notable associations between trajectory patterns and beneficiaries' characteristics.
| Covariate associations with trajectories
While previous research has demonstrated considerable heterogeneity in classes of controlled substance users, [7] [8] [9] [10] [11] [12] this is the first study to examine opioid dispensing trajectories within a specific population of beneficiaries included in an intervention aimed at reducing potential overutilization. Therefore, there is little research to which we can compare our findings. From a broad perspective, studies have identified similar covariates, including mental health disorders, severity of pain conditions, and healthcare utilization, associated with dissimilar classes of controlled substance users. 8, 20 Key covariate differences between C2 and C3 suggest that declines in C3 opioid dispensing post-spike could be attributed to the higher prevalence of overdose events and MAT in this class. Specifically, overdose events could have served as an impetus for MAT and the observed decline in MMEs prior to and during enrollment for some beneficiaries clustering around C3. However, additional research is needed to more closely examine the temporality of these FIGURE 2 Standardized differences in North Carolina Medicaid "lock-in" programenrolled beneficiary characteristics by latent class, using class 5 (ie, "start low, end low" class) as the reference group. MAT, medication-assisted treatment; ED, emergency department; RA/OA, rheumatoid arthritis/osteoarthritis; MH, mental health; class 1 = start high, end high; class 2 = start medium, end medium; class 3 = start medium, end low; class 4 = start low, end medium; class 5 = start low, end low. Refer to online appendix for details on standardized difference calculations. Briefly, standardized differences provide a measure of the similarity or dissimilarity of 2 groups with respect to specific covariates. For example, for "other substance disorders," the figure indicates that beneficiaries who clustered around classes 1, 2, and 4 have a lower prevalence of substance disorders than those who clustered around class 5, and beneficiaries who clustered around class 3 have a somewhat higher prevalence of substance disorders than those who clustered around class 5 associations and to also examine the extent to which mental health disorders and associated treatment may or may not have contributed to the declining pattern. Given that the decline began prior to enrollment in the LIP, beneficiaries clustered around the C3 pattern might have followed a declining pattern post-spike, irrespective of LIP enrollment. Initial sensitivity analyses revealed that the declining pattern was not unique to those enrolled in the LIP but may have also occurred among those eligible for the program but not prioritized for enrollment. However, additional work is needed to further understand the potential contribution of the LIP and other factors to the declining pattern.
Compared with beneficiaries in C5, those following a C4 pattern tended to have a greater prevalence of pain conditions, disability, and comorbidity. If these beneficiaries experienced an onset of new pain conditions, disabilities, and/or comorbidities just prior to meeting LIP eligibility, this might help explain why they escalated and remained elevated at the time that they did, rather than returning to MME dispensing levels similar to pre-spike levels, like C5. Additionally, while it seems likely that the large proportion of MAT may have factored into the restabilization to low levels of dispensed MMEs observed in the C5 trajectory, the majority of beneficiaries clustered around this class did not use MAT. Additional work is needed to understand factors driving the observed spike, and reasons why certain beneficiaries restabilize post-spike while others do not.
| LIP implications
LIPs are generally implemented to reduce potential overutilization of opioids; however, our findings suggest limited impact on average trajectories of MMEs dispensed to beneficiaries over LIP-related periods.
The only class that exhibited a decline in dispensed MMEs during the lock-in period was C3; however, this decline was evident prior to the point of actual LIP enrollment.
Our findings, combined with early evidence from promising LIP designs, 21 suggest that there may be modifications LIPs can make to operate more effectively and improve beneficiary outcomes. For example, given our finding of a strong association of MAT history with generally low MME trajectory patterns, LIP administrators could consider comprehensively integrating a range of substance use disorder assessment and treatment services throughout LIP pre-enrollment and enrollment periods. Additionally, we found that those receiving
Medicaid benefits because of a disability tended to follow paths characterized by higher levels of dispensed MMEs across periods. A focused effort, as part of the LIP, to assess beneficiaries who receive
Medicaid benefits because of a disability and remain at persistently high levels of MMEs for potential opioid tapering, utilization of alternative or complementary pain therapy approaches, and possession of naloxone might improve beneficiary outcomes and reduce overdose risk. 22 While some Medicaid LIPs provide beneficiaries with additional services, most programs do not. 23 Additional work is need to understand which LIP models, including which integrated services, can help both improve the complex health needs of enrolled beneficiaries and reduce healthcare costs from beneficiary and Medicaid perspectives in the short and long term. 
| Limitations
